Furian L, Baldan N, Rigotti P
Department of Medical and Surgical Sciences, Clinica Chirurgica Generale 3, University of Padua, Padua, Italy.
Transplant Proc. 2004 Mar;36(2 Suppl):148S-151S. doi: 10.1016/j.transproceed.2004.01.008.
Cyclosporine (CsA) therapy has evolved considerably since its introduction as the primary immunosuppressant drug in the early 1980s and its use in renal transplantation continues to expand globally. In the last 20 years, there have been significant advances in formulation design, therapeutic drug monitoring guidelines, and the emerging role of CsA-based combination therapies that have resulted in a substantial improvement in clinical outcomes in renal transplant recipients. The aim of this work is to review developments in the application of CsA in kidney transplantation at our Center in Padua and to evaluate the clinical outcome of our patients in the last 15 years in relation to the new trends in CsA management strategies.
自20世纪80年代初作为主要免疫抑制药物引入以来，环孢素（CsA）疗法已经有了很大的发展，其在肾移植中的应用在全球范围内仍在不断扩大。在过去20年中，制剂设计、治疗药物监测指南以及基于CsA的联合疗法的新作用都取得了重大进展，这使得肾移植受者的临床结局有了显著改善。这项工作的目的是回顾CsA在我们帕多瓦中心肾移植中的应用进展，并根据CsA管理策略的新趋势评估我们患者在过去15年中的临床结局。
